Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts von Kasprzak, A., Assadi, C., Nachtkamp, K., Rudelius, M., Haas, R., Giagounidis, A., Götze, K., Gattermann, N., Germing, U.

Volltext

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification von Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A., Aul, C., Blum, S., Hofmann, W. K., Pfeilstöcker, M., Valent, P., Lübbert, M., Seidl, M., Rudelius, M., Stauder, R., Krieger, O., Götze, K. S., Bobak, J., Kündgen, A., Schulz, F., Dietrich, S., Kobbe, G., Gattermann, N., Germing, U.

Volltext

First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas—a single-centre experience in 61 p... von Brezina, T., von Dewitz, H., Schroeder, T., Ullrich, S., Nachtkamp, K., Reifenberger, G., Malzkorn, B., Sabel, M., Haas, R., Kobbe, G.

Volltext

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes von Kasprzak, A., Nachtkamp, K., Kondakci, M., Schroeder, T., Kobbe, G., Kündgen, A., Kaivers, J., Rautenberg, C., Haas, R., Gattermann, N., Bonadies, N., Germing, U.

Volltext

P589: AGE AND AGE‐ADAPTED RISK FACTORS HIGHLY INFLUENCE SURVIVAL PROBABILITY IN AML PATIENTS – A RETROSPECTIVE ANALYSIS von Nachtkamp, K., Zahner, C., Fricke, A., Ulrych, T., Schulz, F. I., Kündgen, A., Jäger, P. S., Kobbe, G., Germing, U.

Volltext

P772: PROGNOSTIC IMPACT OF DISEASE‐RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) von Lesch, C., Kündgen, A., Nachtkamp, K., Kasprzak, A., Strupp, C., Rudelius, M., Gattermann, N., Kobbe, G., Hildebrandt, B., Germing, U.

Volltext

P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY von Schulz, F., Kostova, J., Hildebrandt, B., Nachtkamp, K., Strupp, C., Gattermann, N., Lübbert, M., Blum, S., Parmentier, S., Götze, K., Lipke, J., Beier, F., Hofmann, W.‐K., Germing, U.

Volltext

P532: ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER von Fricke, A., Nachtkamp, K., Döhner, K., Hildebrandt, B., Betz, B., Rudelius, M., Seidl, M., Zahner, C., Kobbe, G., Kündgen, A., Jäger, P. S., Baermann, B.‐N., Germing, U.

Volltext

Validation of a New Clinically Based Classification System for Stratification of Prognosis in Patients with CMML von Rautenberg, C, Schuler, E, Nachtkamp, K, Schroeder, T, Blum, S, Aul, C, Haas, R, Germing, U

Volltext

Patients with IPSS-R Intermediate Risk can be Separated Into Three Risk Groups von Nachtkamp, K, Reykowski, T, Hildebrandt, B, Baldus, S, Rudelius, M, Neukirchen, J, Kündgen, A, Strupp, C, Schroeder, T, Haas, R, Germing, U

Volltext

Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis von Machherndl-Spandl, Sigrid, Sega, W., Bösmüller, H., Germing, U., Gruber, Ch, Nachtkamp, K., Reinecke, P., Sperr, W. R., Wimazal, F., Müllauer, L., Sotlar, K., Horny, H. P., Tüchler, H., Valent, P., Krieger, O.

Volltext

240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE von Pfeilstöcker, M, Tuechler, H, Nachtkamp, K, Platzbecker, U, Schönmetzler, A, Sperr, W, Stauder, R, Strupp, C, Valent, P, Germing, U

Volltext

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) von MALCOVATI, Luca, DELLA PORTA, Matteo G, GERMING, Ulrich, CAZZOLA, Mario, STRUPP, Corinna, AMBAGLIO, Ilaria, KUENDGEN, Andrea, NACHTKAMP, Kathrin, TRAVAGLINO, Erica, INVERNIZZI, Rosangela, PASCUTTO, Cristiana, LAZZARINO, Mario

Volltext

P-093 Hypoplastic myelodysplastic syndromes are not a specific clinical entity von Schemenau, J, Baldus, S.E, Anlauf, M, Blum, S, Nachtkamp, K, Neukirchen, J, Strupp, C, Haas, R, Gattermann, N, Germing, U

Volltext

P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation von Nachtkamp, K, Kündgen, A, Neukirchen, J, Strupp, C, Schroeder, T, Haas, R, Kobbe, G, Gattermann, N, Germing, U

Volltext

O-022 Clinical features, treatment and prognosis in patients with MDS and monosomy 7 von Schanz, J, Nachtkamp, K, Germing, U, Haas, P, Lübbert, M, Müller-Thomas, C, Götze, K, Platzbecker, U, Nolte, F, Haase, D

Volltext

312 Restratification of IPSS risk groups according to the WPSS identifies patients with myelodysplastic syndromes (MDS) at higher risk von Neukirchen, J, Hildebrandt, B, Kuendgen, A, Nachtkamp, K, Haas, R, Gattermann, N, Germing, U

Volltext

P-210 Azacitidine and DLI as salvage therapy for MDS or AML relapse after allo-SCT induces long-term molecular remissions and increases Tregs von Schroeder, T, Lamers, M, Fröbel, J, Cadeddu, R.P, Czibere, A, Pechtel, S, Dienst, A, Nachtkamp, K, Rachlis, E, Platzbecker, U, Bug, G, Uharek, L, Fenk, R, Germing, U, Kröger, N, Haas, R, Kobbe, G

Volltext

O-023 Did the prognosis of MDS patients improve during the last 30 years? von Neukirchen, J, Nachtkamp, K, Pfeilstöcker, M, Valent, P, Stauder, R, Blum, S, Lübbert, M, Haase, D, Götze, K, Hofmann, W.K, Schlenk, R, Giagounidis, A, Aul, C, Schulte, K, Lipke, J, Nusch, A, Krieger, O, Hegener, P, Weik, C, Letsch, A, Platzbecker, U, Kreutzer, K.A, Kobbe, G, Germing, U

Volltext

153 Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the Dusseldorf MDS registry von Nachtkamp, K, Stark, R, Neukirchen, J, Kündgen, A, Giagounidis, A, Haas, R, Gattermann, N, Germing, U

Volltext